Quantcast
Last updated on April 16, 2014 at 7:50 EDT

Latest Angina pectoris Stories

2008-08-27 18:00:56

PALO ALTO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 34 non-executive officers due to additional hiring, primarily in connection with its commercialization efforts in the United States. The inducement stock options cover an aggregate 73,700 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the...

2008-08-25 09:00:26

Passive smoking kills 7 people per day in Brazil RIO DE JANEIRO, Aug. 22 (Xinhua) -- The diseases caused by passive smoking kills seven people per day, or 2,655 people per year in Brazil, according to a study released Friday by the Rio de Janeiro State University and the Cancer Institute. The study shows that passive smoking could cause serious diseases, such as lung cancer, cerebral hemorrhage, angina pectoris, myocardial infection and coronary thrombosis. Scientists also found that...

2008-08-25 09:00:26

Anthera Pharmaceuticals has started the Francis clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an acute coronary syndrome event. The Francis trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It will enroll up to 500 patients that will be treated for a minimum of six months. The study will be conducted at sites in North America and Europe. Francis will provide...

2008-08-24 22:57:20

By Annie Freeda Cruez THE journalist was on his way to a nasi lemak breakfast with a colleague when he slumped in the car seat and died. He was just 41. A pulmonary and critical care physician tells ANNIE FREEDA CRUEZ that doctors are seeing more and more young people with coronary heart diseases. The modern sedentary lifestyle is the biggest culprit in the growing number of heart-related diseases in the country. Kuala Lumpur Hospital's consultant pulmonary and critical care physician,...

2008-08-22 03:00:11

By Pacileo, M Cirillo, P; De Rosa, S; Chiariello, M Dear Editor, We read with great interest the study by Bertz et ai in the last issue of International Angiology, dealing with differences of inflammatory biomarker (i.e. neopterin and (alpha- TNF) levels between diabetic and non-diabetic patients with critical limb ischemia.1 Recent reports have found increased serum levels of neopterin in patients with cardiovascular disease. Thus, several authors have proposed that increased plasma...

2008-08-19 09:01:12

PALO ALTO, Calif., Aug. 19 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that the Journal of Cardiovascular Electrophysiology has published a study of ranolazine showing that ranolazine significantly (p In the study, five patients with LQT3 syndrome were prospectively investigated during an eight hour intravenous infusion of therapeutic concentrations of ranolazine, with ECG and ECHO evaluation before, during and after ranolazine administration. LQT3 syndrome is caused...

2008-08-14 18:00:45

PALO ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that it has received approval from the European Medicines Agency (EMEA) for the brand name Ranexa(R) (ranolazine). On July 10, 2008, the Company announced that the EMEA had granted marketing authorization for ranolazine in all 27 European Union (EU) member states under the brand name Latixa. "Securing approval for the Ranexa brand name in Europe provides important brand synergy in the world's two...

2008-08-14 15:00:59

PALO ALTO, Calif., Aug. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. today announced that its chronic angina therapy Ranexa(R) (ranolazine extended-releases tablets) has been selected as a finalist for the prestigious Prix Galien USA 2008 award which honors the best pharmaceutical agent and best biotechnology product of the year. Winners will be announced on September 24, 2008 in New York. "Being named a finalist for the Prix Galien USA awards is a great honor. We congratulate the...

2008-06-30 18:02:10

MONTVALE, N.J., June 30, 2008 (PRIME NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electroceutical(r) therapy systems designed to enhance the body's natural anti-inflammatory response, today announced that the Cleveland Clinic, in Westin, Florida, has released the results of its double-blind, randomized, placebo-controlled and prospective clinical trial (EFFECT trial) utilizing the Company's proprietary targeted pulsed electromagnetic field (tPEMF(tm))...

2008-06-26 12:03:21

U.S. cardiologists have discovered nearly 1-in-5 patients experiences chest pain one year after suffering a heart attack. Dr. Thomas Maddox and colleagues at the Denver Veterans Affairs Medical Center and University of Colorado studied the occurrence of angina (episodic chest pain) in 1,957 patients from January 2003 to June 2004. The study showed of all patients, 389 (19.9 percent) reported angina one year after hospitalization for heart attack. Those patients were more likely to be...